Immunotherapy and Cancer
A continuing medical education activity sponsored by NAMCP and AAMCN.
This activity is an archive from the
live session at the 2016 Fall Forum. If you participated in
the live session, you are not eligible for continuing education
credits from this archive.
This activity is valid from January 1, 2017 to December 31, 2017
Instructions for CME/CNE: Complete the pre-test, listen to the audio
and view the slides, complete the post test, complete the evaluation
form and hit submit. You will be asked to enter your name and email
address on the pre-test, evaluation and post-test. If you close your
internet browser without completing the post test, you will have ONE
more opportunity to complete. A score of 70% must be achieved on the
post test to receive continuing education credits. If you do not
pass the post test after two attempts, you will not be eligible to
try again. Once you complete the evaluation form and score 70% or
higher on your post test, you will automatically be given your
certificate. To print or save your certificate, you will need
to click on the “download” button and either print or save.
Audience: This activity is intended for
healthcare professionals practicing in managed care environments.
This activity is supported by
an educational grant from
Cancer immunotherapy is the use of the immune system to treat
cancer. Immunotherapies can be categorized as active, passive or
hybrid (active and passive). These approaches exploit the fact that
cancer cells often have molecules on their surface that can be
detected by the immune system, known as tumourassociated antigens (TAAs);
they are often proteins or other macromolecules (e.g.
carbohydrates). Active immunotherapy directs the immune system to
attack tumor cells by targeting TAAs. Passive immunotherapies
enhance existing anti-tumor responses and include the use of
monoclonal antibodies, lymphocytes and cytokines. Advances in the
understanding of the immune system are changing the way the
interprofessional healthcare team manages cancer. As immunotherapies
move to the forefront of cancer treatment, healthcare professionals
will need to understand the immune system; know how cancer
circumvents it; and be aware of the mechanisms of action, efficacy,
and safety of current and emerging immunotherapies.
The development of immunotherapies to treat cancer has transformed
the way clinicians think about managing their patients with many
forms of malignancies. The speed, at which basic science and
clinical trial information continues to emerge in this area, creates
practice and/or educational gaps for busy clinicians who strive to
maintain state-of-the art care for their patients with cancer. This
field is one of the most clinically relevant and exciting areas of
novel drug development in oncology.
Upon Completion of this
activity, participants will be able to:
Analyze the mechanisms of action
behind immune response to cancer and the role of immunotherapy
in cancer treatment
Compare and contrast new and
emerging immunotherapy classes and individual agents and their
efficacy, safety, and potential patient responses to therapy in
Describe how recent data on immuno-oncology
can be placed in the context of evolving treatment paradigms and
combination strategies in clinical development
Discuss strategies to counsel and
assist patients to overcome barriers to therapy, including
treatment side effects to improve adherence to therapy
||Thomas Morrow, MD
Chief Medical Officer, Vivio Health
Chief Medical Officer, NextIT
has no financial relationships to disclose but owns
stock in a variety of biotech companies. His
presentation has been peer reviewed for any bias.
Bill Williams, MD has no real or perceived financial
relationships to disclose.
Jacquelyn Smith, RN, BSN, MA, CMCN has no real or
perceived financial relationships to disclose.
Katie Eads has no real or perceived financial
relationships to disclose.
Will Williams has no real or perceived financial
relationships to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity.
Accreditation & Designation
The National Association of Managed Care Physicians is
accredited by the Accreditation Council for Continuing Medical
Education to provide continuing medical education to physicians.
The National Association of Managed Care Physicians designates this
live activity for a maximum of 1 AMA PRA Category 1 Credits™.
Physicians should only claim credit commensurate with the extent of
their participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of continuing nursing education by the American Nurses
Credentialing Center’s Commission on Accreditation. Nurses who
complete this activity and turn in a validation form will receive up
to 1 credit in continuing nursing education.
The American Board of Managed Care Nurses has approved this activity
for a maximum of 1 contact hour towards CMCN recertification.
This activity is
supported by an educational grant from
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
Click Here To Continue